NASDAQ:EDGE Edge Therapeutics (EDGE) Stock Price, News & Analysis → What is Nvidia’s New $1 Trillion Superproject? (From Weiss Ratings) (Ad) Free EDGE Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$3.34▼$3.6150-Day Range$0.50▼$6.7152-Week Range$0.28▼$17.38Volume350,887 shsAverage Volume373,201 shsMarket Capitalization$106.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsHeadlinesSocial MediaStock AnalysisCompetitorsHeadlinesSocial Media Get Edge Therapeutics alerts: Email Address Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion Superproject?Nvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. About Edge Therapeutics Stock (NASDAQ:EDGE)PDS Biotechnology Corp. engages in the development of clinical-stage immunotherapies to treat various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products PDS0101, is an off the shelf immunotherapeutic that is administered by subcutaneous injection. The company was founded by Frank K. Bedu-Addo on March 15, 2019 and is headquartered in Princeton, NJ.Read More Ad Weiss RatingsWhat is Nvidia’s New $1 Trillion Superproject?Nvidia recently added $277 billion in market cap … IN ONE DAY.Find out details on these three critical Nvidia partners immediately. EDGE Stock News HeadlinesMay 21 at 10:55 AM | finance.yahoo.comIntrommune Therapeutics Presents Oral Mucosal Immunotherapy Updates at Leading Industry EventsMay 21 at 10:55 AM | finance.yahoo.comRactigen Therapeutics Secures FDA Fast Track Designation for RAG-01, a First-in-Class saRNA TherapyMay 20 at 1:22 PM | markets.businessinsider.comBuy Rating Affirmed: Autolus Therapeutics’ Strategic Position and Upcoming Catalysts Promise Upside PotentialMay 17, 2024 | finance.yahoo.comPsychedelicNewsWire Named Official Media Sponsor of the 4th Annual Psychedelic Therapeutics and Drug Development ConferenceMay 16, 2024 | markets.businessinsider.com4th Annual Psychedelic Therapeutics and Drug Development Conference Scheduled for May 23-24 in Boston, MAMay 14, 2024 | finance.yahoo.comATED Therapeutics Ltd. Finalist in Health Products Category of Fast Company’s 2024 World Changing Ideas AwardsMay 14, 2024 | markets.businessinsider.comTavros Therapeutics Achieves Two Milestone Payments in its Collaboration with Vividion TherapeuticsMay 12, 2024 | seekingalpha.comWhat Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma PartnerMay 12, 2024 | seekingalpha.comWhat Makes Viking Therapeutics An Attractive Takeover Target Or Big Pharma PartnerMay 10, 2024 | markets.businessinsider.comKey Takeaways From Relay Therapeutics Analyst RatingsMay 9, 2024 | finance.yahoo.comLisata Therapeutics Net Loss Declines From a Year EarlierMay 9, 2024 | finance.yahoo.comCB Therapeutics Introduces Sustainable Retinol ProductionMay 7, 2024 | finance.yahoo.comTopas Therapeutics Appoints Hugo Fry as CEOMay 7, 2024 | markets.businessinsider.comAtopia Therapeutics, Formerly HpVac, Announces Appointment of Dr. Gregoire Chevalier as CEO and Business UpdateMay 3, 2024 | markets.businessinsider.comOptimistic Buy Rating for Dyne Therapeutics Backed by Promising DYNE-101 Drug Efficacy DataMay 2, 2024 | uk.finance.yahoo.comCorcept Therapeutics Inc (CORT) Q1 2024 Earnings Call Transcript Highlights: Strong Growth Amid ...May 2, 2024 | finanznachrichten.de500Newswire, LLC: CB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comCB Therapeutics Unveils Revolutionary Breakthroughs in Crafting Pharmaceutical-Grade Cannabinoids and AnaloguesMay 2, 2024 | finance.yahoo.comKelonia Therapeutics to Participate in Upcoming Scientific ConferencesApril 30, 2024 | finance.yahoo.comAsimov Achieves 10x Improvement in Lentiviral Production, Launches New Stable Cell Line Development ServiceApril 29, 2024 | finanznachrichten.deEVOX THERAPEUTICS LIMITED: Evox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerApril 29, 2024 | markets.businessinsider.comEvox Therapeutics Names Co-Founder Dr. Per Lundin as Chief Executive OfficerApril 26, 2024 | finance.yahoo.comRactigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBCApril 26, 2024 | msn.comMundipharma to acquire rezafungin assets from Cidara TherapeuticsApril 26, 2024 | msn.comFDA approves Utility Therapeutics’ Pivya tablets for UTIsSee More Headlines Receive EDGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Edge Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/01/2018Today5/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:EDGE CUSIPN/A CIK1472091 Webwww.edgetherapeutics.com Phone(800) 208-3343FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,860,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.29% Return on Assets-56.92% Debt Debt-to-Equity RatioN/A Current Ratio5.59 Quick Ratio5.59 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.95 per share Price / Book3.56Miscellaneous Outstanding Shares31,510,000Free FloatN/AMarket Cap$106.50 million OptionableNot Optionable Beta3.65 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesFrank K. Bedu-AddoPresident, Chief Executive Officer & DirectorMichael P. KingChief Financial OfficerLauren WoodChief Medical OfficerGregory L. ConnChief Scientific OfficerJanetta TrochimiukControllerKey CompetitorsDiaMedica TherapeuticsNASDAQ:DMACRezoluteNASDAQ:RZLTImmunicNASDAQ:IMUXPMV PharmaceuticalsNASDAQ:PMVPBeyondSpringNASDAQ:BYSIView All Competitors EDGE Stock Analysis - Frequently Asked Questions How were Edge Therapeutics' earnings last quarter? Edge Therapeutics, Inc. (NASDAQ:EDGE) announced its earnings results on Thursday, November, 1st. The biotechnology company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.16. What other stocks do shareholders of Edge Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Edge Therapeutics investors own include ContraFect (CFRX), Amicus Therapeutics (FOLD), McEwen Mining (MUX), Cerecor (CERC), Synergy Pharmaceuticals (SGYP), Arena Pharmaceuticals (ARNA), BioLineRx (BLRX), Corbus Pharmaceuticals (CRBP), CRISPR Therapeutics (CRSP) and Fate Therapeutics (FATE). This page (NASDAQ:EDGE) was last updated on 5/23/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesWrite this ticker symbol down…StocksToTradeElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaElon to Transform U.S. Economy? Porter & Company41 banks launch ‘crypto dollar’Stansberry ResearchDaily Options Pick (Delivered)Prosper Trading AcademyThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edge Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.